Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tempest Therapeutics Inc.

6.90
-0.1900-2.68%
Pre-market: 6.900.00000.00%08:05 EDT
Volume:79.87K
Turnover:562.22K
Market Cap:28.20M
PE:-0.35
High:7.18
Open:7.05
Low:6.90
Close:7.09
Loading ...

Tempest Receives Orphan Drug Designation From the FDA for Tpst-1495 to Treat Patients With Fap

THOMSON REUTERS
·
21 Apr

Tempest Therapeutics Inc - Phase 2 Study of Tpst-1495 in Fap Patients to Begin This Year

THOMSON REUTERS
·
21 Apr

Tempest Therapeutics Inc - Data From Phase 2 Study Expected in 2026

THOMSON REUTERS
·
21 Apr

Tempest Therapeutics Inc - Expects $1.5 Million in Cash Expenditures - SEC Filing

THOMSON REUTERS
·
19 Apr

Tempest Therapeutics Cut to Sector Perform From Sector Outperform by Scotiabank

Dow Jones
·
10 Apr

HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy

MT Newswires Live
·
10 Apr

Tempest Therapeutics Inc : Scotiabank Cuts to Sector Perform From Sector Outperform; Raises Target Price to $9 From $7

THOMSON REUTERS
·
10 Apr

BUZZ-Tempest rises as company eyes potential merger to advance liver cancer drug

Reuters
·
10 Apr

Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives

Dow Jones
·
10 Apr

Tempest Therapeutics to explore strategic alternatives

TIPRANKS
·
10 Apr

Tempest Therapeutics : Strategic Alternatives May Include, but Are Not Limited to, Mergers, Acquisition, Partnerships, Joint Ventures

THOMSON REUTERS
·
10 Apr

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

THOMSON REUTERS
·
10 Apr

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

GlobeNewswire
·
10 Apr

BRIEF-Tempest Therapeutics Announced 1-For-13 Reverse Stock Split

Reuters
·
07 Apr

Tempest Therapeutics Inc - on April 4, Announced 1-for-13 Reverse Stock Split - SEC Filing

THOMSON REUTERS
·
07 Apr

Tempest Therapeutics treatment of FAP granted FDA orphan designation

TIPRANKS
·
01 Apr

Scotiabank Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)

TIPRANKS
·
29 Mar

Piper Sandler Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)

TIPRANKS
·
29 Mar

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kodiak Sciences (KOD), Tempest Therapeutics (TPST) and EDAP TMS (EDAP)

TIPRANKS
·
29 Mar

Tempest Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar